The company released GPT-5-Codex, a variant of GPT-5 that is optimized for Codex, OpenAI’s AI coding agent. It was trained on ...

Your weekly strategic brief on the cyber threat landscape. Uncover the deeper patterns behind attacks, from bootkit malware ...

Alphabet stock jumped over 7% on Tuesday after a judge ruled that Google can keep Chrome and Android but must share data with rivals, a decision reshaping competition and boosting Apple, too. This ...

Andrew Stanton is a Newsweek weekend reporter based in Maine. His role is reporting on U.S. politics and social issues. Andrew joined Newsweek in 2021 from The Boston Globe. He is a graduate of ...

After the initial wave of M3 Expressive, the Gmail for Android redesign continues by placing each email in a container. The Material 3 Expressive redesign that widely rolled out, which Google ...

The American Dream is alive and well in these prosperous places. The 50 richest and safest cities in the US have been unveiled in a new list — and it doesn’t look good for the Empire State. New York ...

Rajesh started following the latest happenings in the world of Android around the release of the Nexus One and Samsung Galaxy S. After flashing custom ROMs and kernels on his beloved Galaxy S, he ...

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

Sign up for the Slatest to get the most insightful analysis, criticism, and advice out there, delivered to your inbox daily. The reality of what’s happening in D.C ...

The database helps companies calculate their greenhouse gas emissions. Its creator left the E.P.A. after being investigated for criticizing the Trump administration. By Harry Stevens The Environmental ...

Jean Joseph, a data & AI engineer with deep expertise in database development, will explain how to build AI-powered applications with Azure Database for PosgreSQL at at upcoming developer conference.

Pirtobrutinib had a nominally superior overall response rate compared to ibrutinib in certain patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The non-covalent ...